The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Screening and surveillance of hepatocellular carcinoma

간암의 조기진단

  • Lee, Myung-Ah (Division of Oncology, Department of Internal Medicine, The Catholic University of Korea College of Medicine)
  • 이명아 (가톨릭대학교 의과대학 내과학교실)
  • Published : 2010.09.01
⟨ Previous Next ⟩

Abstract

Hepatocellular carcinoma (HCC) is common cancer in Korea. Although HCC has been decreased recently, mortality rate is still high, especially in the 6th decades in men. While hepatitis B and C viral hepatitis is the most common cause of HCC, alcoholic hepatitis is being the major risk factor in Korea. For early detection of HCC, it is important to identify the risk group and to monitor with regular interval. Serum alpha fetoprotein and abdominal ultrasonography is mainstay for screening of HCC. Recently, new advanced techniques, including new biomarkers have been developed and introduced, but it is not certain for its usefulness as a screening method. The screening program suggested by National Cancer Center and associated society of liver disease is widely used in Korea. Based on screening programs, individual personalized surveillance program is needed for the high risk patients in practice.

Keywords

References

  1. Carr BI. Tumors of the liver and biliary tree. In: Fauci S, Braunwald E, Kasper DL Hauser SL, Longo DL, Jameson JL, Loscalzo J, eds. Harrison's textbook of medicine, 17th ed. McGraw-Hill
  2. 보건복지가족부 중앙 암등록 본부. 2006-2007년 암 발생률
  3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005 https://doi.org/10.3322/canjclin.55.2.74
  4. Jung SH, Kim BH, Joung YH, Han YS, Lee BH, Dong SH, Kim HJ, Chang YW, Lee JI, Chang R. Clinical features of hepatocellular in the 1990s. Korean J Gastroenterol 42: 322-329, 2003
  5. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 15:948-963, 1992 https://doi.org/10.1002/hep.1840150532
  6. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: world wide incidence and trends. Gastroenterology 127(5 suppl1):S5-S16, 2004
  7. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver dis 30:3-16, 2010 https://doi.org/10.1055/s-0030-1247128
  8. Bruix J, Sherman M. Practice guidelines committee, American Association for the study of liver diseases. Management of hepatocellular carcioma. Hepatology 42:1208-1236, 2005 https://doi.org/10.1002/hep.20933
  9. Huh K, Choi SY, Whang YS, Lee DS. Prevalence of viral hepatitis markers in Korean patients with hepatocellular carcinoma. J Korean Med Sci 13:306-310, 1998
  10. Brechot C, Kremsdorf D, Soussan P, Pineau P, Dejean A, Paterini-Brechot P, Tiollais P. Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): Molecular mechanisms and novel paradigms. Pathol Biol 58:278-287, 2010 https://doi.org/10.1016/j.patbio.2010.05.001
  11. 박중원. 간세포암종: 개관과 현황. 대한소화기학회지 45:217-226, 2005
  12. Cabibbo G, Craxi A. Hepatocellular cancer: optimal strategies for screenig and surveillance. Dig Dis 27:142-147, 2009 https://doi.org/10.1159/000218346
  13. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ. Risk factors for hepatocellular carcinoma: synergism of alcholol with viral hepatitis and diabetes mellitus. Hepatology 36:1206-1213, 2002 https://doi.org/10.1053/jhep.2002.36780
  14. Park SC, Oh SI, Lee, MS. Korean status of alcoholics and alcohol-related health problems. Alcohol Clin Exp Res 22(3 Suppl):170S-172S, 1998
  15. 안상훈, 한광협, 윤영훈, 홍성필, 백용한, 전재윤, 문영명, 송기준, 김동기, 서일. 한국인에서 간암발생의 위험요인 분석. 대한내과학회지 60:123-130, 201
  16. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123:134-140, 2002 https://doi.org/10.1053/gast.2002.34168
  17. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospecitvely studied cohort of U.S. adults. N Engl J Med 348:1625-1638, 2003 https://doi.org/10.1056/NEJMoa021423
  18. Yun EH, Lim MK, Oh JK, Park JH, Shin A, Sung J, Park EC. Combined effect of socioeconomic status, viral hepatitis, and lifestyle on hepatocellular carcinoma risk in Korea. Br J Cancer 20(Epub ahead of print), 2010 https://doi.org/10.1038/sj.bjc.6605803
  19. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, Morabito A, De Franchis R, Colombo M. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126:1005-1014, 2004 https://doi.org/10.1053/j.gastro.2003.12.049
  20. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130: 417-422, 2004
  21. Tresvani F, D'lntino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notaris S, Roda E, Bernardi M. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34:570-575, 2001 https://doi.org/10.1016/S0168-8278(00)00053-2
  22. Di Bisceglie AM, Hoofnagle JH. Elevation in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer 64:2117-2120, 1989 https://doi.org/10.1002/1097-0142(19891115)64:10<2117::AID-CNCR2820641024>3.0.CO;2-7
  23. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok AS, Lee WM, Morgan TR, Ghany MG, Gretch DR; HALT-C Trial Group. Serum alpha fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 43:434-441, 2005 https://doi.org/10.1016/j.jhep.2005.03.019
  24. Lee HS, Ching YH, Kim CY. Specificities of serum alpha-fetoprotein in HBs Ag (+) and HBs Ag (-) patients in the diagnosis of hepatocellular carcinoma. Hepatology 14:68-72, 1991 https://doi.org/10.1002/hep.1840140112
  25. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 5:145-159, 2001 https://doi.org/10.1016/S1089-3261(05)70158-6
  26. Colombo M. Screening for cancer in viral hepatitis. Clin Liver Dis 5:109-122, 2001 https://doi.org/10.1016/S1089-3261(05)70156-2
  27. Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroeneterol 16:418-424, 2010 https://doi.org/10.3748/wjg.v16.i4.418
  28. Carr BI, Kanke F, Wise M, Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 52:776-782, 2007 https://doi.org/10.1007/s10620-006-9541-2
  29. Sterling RK, Jefflers L, Gordon F, Sherman M, Venook AP, Reddy KR, Satomura S, Schwartz ME. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroeterol 102:2196-2205, 2007 https://doi.org/10.1111/j.1572-0241.2007.01405.x
  30. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, Boix L, Sala M, Varela M, Liovet JM, Bru C, Bruix J. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47:97-104, 2008
  31. Bolondi L, Sofia S, Siringo S, Galani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zaneetti M, Sherman M. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 48:251-259, 2001 https://doi.org/10.1136/gut.48.2.251
  32. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 27:273-278, 1998 https://doi.org/10.1002/hep.510270140
  33. Lim JH, Choi D, Kim SH, Lee SJ, Lee WJ, Lim HK, Kim S. Detection of hepatocellular carcinoma: value of adding delayed phase imaging to dual-phase helical CT. AJR Am J Roentgenol 179:67-73, 2002
  34. Trevisani F, De NS, Rapaccini G, Farinati F, Benvegnu L, Zoli M, Grazi GL, Del PP, Di N, Bernardi M; Italian Liver Cancer Group. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival(Italian experience). Am J Gastroenterol 97:734-744, 2002 https://doi.org/10.1111/j.1572-0241.2002.05557.x
  35. Santagostino E, Colombo M, Rivi M, Rumi MG, Rocino A, Linari S, Mannucci PM. Study group of the association of Italian hemophilia centerss. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 102:78-82, 2003 https://doi.org/10.1182/blood-2002-10-3310
  36. Kim DY, Han KH, Ahn SA. Semiannual surveillance for hepatocellular carcinoma improved patient survival compared to annual suerveillance (Korean experience) Hepatology (abstract) 46:403A, 2007 https://doi.org/10.1016/j.jhep.2006.09.019
  37. Colombo M. Screening and diagnosis of hepatocellular carcinoma. Liver Int 29:143-147, 2009
  38. Management of hepatocellular carcinoma in Asia. Consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10:1111-1118, 2009 https://doi.org/10.1016/S1470-2045(09)70241-4